Gilead Sciences, Inc. $GILD Stock Position Lifted by Sax Wealth Advisors LLC

Sax Wealth Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,453 shares of the biopharmaceutical company’s stock after purchasing an additional 236 shares during the period. Sax Wealth Advisors LLC’s holdings in Gilead Sciences were worth $272,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Vanguard Group Inc. lifted its stake in Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the last quarter. Nuveen LLC acquired a new stake in Gilead Sciences in the first quarter valued at approximately $620,415,000. Finally, Robeco Institutional Asset Management B.V. lifted its stake in Gilead Sciences by 12.5% in the second quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company’s stock valued at $414,948,000 after acquiring an additional 417,237 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.08.

Gilead Sciences Trading Down 1.3%

Shares of GILD stock opened at $116.74 on Friday. Gilead Sciences, Inc. has a 1 year low of $84.17 and a 1 year high of $121.83. The firm’s fifty day simple moving average is $114.57 and its 200 day simple moving average is $110.19. The firm has a market capitalization of $144.85 billion, a P/E ratio of 23.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares of the company’s stock, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,402,130 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.